Netherlands
The Doetinchem Cohort Study is a population based cohort, focussed on lifestyle and chronic diseases. About 6,000 individuals aged 20-59 years entered the study during 1987-1991, and are re-examined every five years. For each round of investigation biological samples (plasma, serum, buffy coats) have been stored.
| Name of the connected EIT Health partner: | |
| Number of individuals: | 6000 |
| Biobank confirmed willingness to provide samples/data for EIT Health studies: | Yes, but not private industry |
| Contact person(s) and contact data (e-mail address, tel. no) for access purposes: |
Monique Verschuren (PI), Monique.verschuren@rivm.nl, +31 33 2743508; Susan Picavet (project leader), susan.picavet@rivm.nl, +31 33 2743063 |
| Number of samples: | |
| Sample type: | Buffy Coat; Plasma; Serum; Urine; DNA |
| Website: | https://www.rivm.nl/doetinchem-cohort-studie |
| Type of biobank: | Population; Longitudinal |
| If longitudinal the frequency: | Every 5 years |
| Link to central portal to seek samples and data: | |
| Broad consent: | Yes |
| Option to recall donors: | Yes |
| Option to recall family members: | No |
| Major terms for access: | Contact the principal investigator. |
| Ethical and legal compliance: | Approved by medical ethics committee |
| Speed and reliability of delivery: | Depending on the nature of the collaboration, we ask a lumpsum contribution to maintenance of the data collection up to 5 kE, and (if needed) the costs for datamanagement/retrieval.’ |
| Pricing: |
| Storage: | A total of 25 ml of non-fasting venous blood is collected in every round using three types of vacutainers: NaF, serum and EDTA. Samples are centrifuged and aliquoted in 25 cryovial tubes, including plasma, serum, erythrocytes and buffy coat. Standard storage is at -80˚ C. Blood samples are available for all participants for all rounds, though there are some differences per measurement round refer-ring to storage conditions (in round 1 only -20˚ C, and additional -196˚ C storage in round 2 only) or number of tubes. From round 5 onwards we took spot urine samples and stored those at -80˚ C, after testing the sample for urinary tract infection. |
| Compliance with international standards: | |
| Current ISO certificates: |
| Clinical data linked to samples: | Questionnaire data; Clinical data; GWAS; Height, weight, blood pressure (arm and ankle), lung function, waist and hip circumference, heel bone mass (from round 5 onwards), AGEs (from round 6 onwards), hand grip test/balance test/chair test (from round 5 onwards), cognitive functioning; mortality, hospital discharge by diagnosis, cancer registere, pharmacy register |
| Data standards: | |
| Data security rules: |
| Research support, what type of expertise?: | |
| Core facility services; what type? Link?: | |
| Queries from national health registers: | |
| Links to the model contract and MTA: |
| IP rules, what is negotiable?: | |
| Requirements to study results (access etc.): | |
| Participant’s right to the information: | |
| Number of access contracts with industry: |
Access to biological samples from patients with COVID-19?
|
|
| Contact person(s) and contact data (e-mail address, tel. no) for access purposes |